Meg Heim
Meg Heim as VP, Global Head Strategic Scientific Engagement, Operations and Program Management, is a key member of the CMO Office. Meg’s role participates as a member of various Global teams and committees to further strengthen and globalize the Medical function across all Business Units and Countries.
Meg is responsible for crafting and executing the Integrated Scientific Strategy, harmonize Medical Systems, CRMs, Transparency Systems and lead the Innovative Scientific Congress model of the future.
Meg has held officer roles and Executive Global Medical, Sales and Marketing positions with a number of healthcare, medical device and health information technology companies.
Meg is a Registered Nurse with a Masters in Administrative Science, with Post Masters certificates in Non-Profit Organizational Development and Global Leadership from Fairleigh Dickinson University.
Tamas Koncz
Tamas Koncz, MD, MSc, Ph.D., is Chief Medical Officer (CMO) for the Inflammation and Immunology (I&I) Business at Pfizer. As CMO, Tamas leads the medical affairs organization, medical professionals across the world who are responsible for ensuring the safe and effective use of Pfizer I&I medicines, as well as continuous data generation and dissemination to advance the understanding of the medicines’ benefit: risk profiles. Medical affair colleagues are also involved in projects supporting research and early and late phase development, regulatory affairs, reimbursement and lifecycle management of the medicines. Throughout his career, Tamas has held various roles as a VP Global TA Lead, Global and European Medical Director, UK country medical adviser, health economist working with a broad portfolio and medical devices. Tamas holds an MD from the University of Debrecen, Hungary. Additionally, he completed an MSc in Economics at the Corvinus University, Budapest, an MSc in Health Economics at the University of York, UK and an MSc in Pharmaceutical Medicine at the University of Surrey, UK. Tamas also holds a Ph.D. from Semmelweis University, Hungary.
Faisal Mehmud
Faisal joined BMS in July 2016 initially to lead the UK and Ireland Medical organisation, and is now Head of the European Medical group.
He has held a variety of senior leadership roles, most recently at Novartis in the USA, where he was the Vice President of US Clinical Development and Medical Affairs Oncology. Previously he was at GSK, where he was Head of the USA North American Medical Affairs/Clinical Development group for Oncology & Haematology and prior to this he held several roles of increasing seniority at GSK in the UK and at Sanofi in the UK and Paris, France (corporate).
He has extensive experience in late phase drug development, interaction with regulators, HTA bodies and academic co-operative groups globally over 15 years in a variety of therapeutic areas.
Faisal graduated in Medicine from Cambridge University, and before his time in industry, was a practicing physician in the UK in general medicine and oncology.
